help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

The Oncologist, Vol. 13, No. 1, 25-38, January 2008; doi:10.1634/theoncologist.2007-0097
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boss, D. S.
Right arrow Articles by Schellens, J. H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boss, D. S.
Right arrow Articles by Schellens, J. H. M.

Clinical Pharmacology: Concise Drug Reviews

Application of PET/CT in the Development of Novel Anticancer Drugs

David S. Bossa, Renato Valdes Olmosb, Michiel Sinaasappelb, Jos H. Beijnena,c,d, Jan H. M. Schellensa,c

aDivision of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; bDepartment of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands; cUtrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht, The Netherlands; dDepartment of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands

Key Words. Positron emission tomography • Radiopharmaceuticals • Drug evaluation • Neoplasms

Correspondence: Jan H. M. Schellens, M.D., Ph.D., The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Telephone: 31-20-512-2569; Fax: 31-20-512-2572; e-mail: jhm{at}nki.nl

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Combined positron emission tomography/computed tomography (PET/CT) is a relatively new imaging modality, combining the functional images of PET with the anatomical information of CT. Since its commercial introduction about 5 years ago, PET/CT has become an important tool in oncology. Currently, the technique is used for primary staging and restaging of cancer patients, as well as for surgery and radiation therapy planning. The abilities of PET/CT to measure early treatment response as well as drug distribution within the body make this technique very useful in the development of novel anticancer drugs. In this paper, the recent literature on the current role of PET/CT in drug development is reviewed.




This article has been cited by other articles:


Home page
 Ann OncolHome page
C. McCabe, L. Bergmann, N. Bosanquet, M. Ellis, H. Enzmann, M. von Euler, B. Jonsson, K.-J. Kallen, D. Newling, V. Nussler, et al.
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
Ann. Onc., March 1, 2009; 20(3): 403 - 412.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. J. M. Siemerink, N. H. Mulder, A. H. Brouwers, and G. A. P. Hospers
18F-Fluorodeoxyglucose Positron Emission Tomography for Monitoring Response to Sorafenib Treatment in Patients with Hepatocellular Carcinoma
Oncologist, June 1, 2008; 13(6): 734 - 735.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.